USFDAJun 3, 2026, 10:02 AM
Nymox to Resubmit Nymozarfex for US Marketing Approval
AI Summary
Nymox Pharmaceutical Corporation is focusing on re-submitting Nymozarfex for US marketing approval after its initial submission was not accepted for review. The company's subsequent submissions to Denmark and UK agencies were accepted for full review but were initially refused, though updated re-submissions are a possibility. Nymox believes it possesses the necessary clinical and scientific data, despite reviewer skepticism regarding the placebo effect and long-term efficacy. However, additional financing will be required for these updated re-submissions.
Key Highlights
- Nymox plans re-submission of Nymozarfex for US marketing approval after initial rejection.
- Initial US submission for Nymozarfex was not accepted for review.
- Subsequent submissions to Denmark and UK agencies were accepted for full review but initially refused.
- Updated re-submissions to EU agencies are possible but require additional financing.
- Reviewers expressed skepticism regarding the one-year persistence of the placebo effect.
- Reviewers questioned the practical benefits of longer-term efficacy in chronic conditions.
- Independently audited Phase 3 long-term data showed a p-value of .0003 vs placebo.
Price Impact